By William Gullotti
Buffalo, N.Y., Feb. 8 – GS Finance Corp. priced $2.55 million of 0% market-linked securities – autocallable with leveraged upside participation and fixed percentage buffered downside due Jan. 28, 2027 linked to the stock performance of Humana Inc., Bristol-Myers-Squibb Co. and Sanofi, according to a 424B2 filing with the Securities and Exchange Commission.
The notes will be automatically called at par plus a 36.2% premium if each stock closes at or above its initial level on Jan. 29, 2025.
The payout at maturity will be par plus 300% of any gain in the least performing stock.
Investors will receive par if the worst performer falls by no more than 25% and will lose 1% for every 1% decline of the worst performer beyond 25%.
The securities are guaranteed by Goldman Sachs Group, Inc.
Wells Fargo Securities LLC and Goldman Sachs & Co. LLC are the agents.
| Issuer: | GS Finance Corp.
|
| Guarantor: | Goldman Sachs Group, Inc.
|
| Issue: | Market-linked securities – autocallable with leveraged upside participation and fixed percentage buffered downside
|
| Underlying stocks: | Humana Inc., Bristol-Myers-Squibb Co., Sanofi
|
| Amount: | $2,554,000
|
| Maturity: | Jan. 28, 2027
|
| Coupon: | 0%
|
| Price: | Par
|
| Payout at maturity: | Par plus 300% of any gain of least performing stock; if worst performer falls by up to 25%, par; otherwise, 1% loss for every 1% decline of worst performer beyond 25%
|
| Call: | Automatically at par plus a 36.2% premium if each stock closes at or above its initial level on Jan. 29, 2025
|
| Initial levels: | $50.24 for Bristol-Myers-Squibb, $402.40 for Humana, $49.89 for Sanofi
|
| Buffer levels: | 75% of initial levels
|
| Pricing date: | Jan. 24
|
| Settlement date: | Jan. 29
|
| Agent: | Wells Fargo Securities LLC and Goldman Sachs & Co. LLC
|
| Fees: | 2.575%
|
| Cusip: | 40057XWS0
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
